Anavex Life Sciences Corp. is filing definitive proxy materials and prioritizing engagement with the FDA and SEC regarding its regulatory path.

The entities involved

• FDA →
  • The illegal U.S. vape market is estimated to be worth $9 billion, fueled by unauthorized imports from China, while products must meet FDA authorization standards.Sun 20:36
  • VDPHL01 and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.Sun 20:31
• Securities and Exchange Commission →

  government agency of the Philippines

  • BlackRock filed disclosures with the SEC regarding the iShares 0-3 Month Treasury Bond ETF.Sun 13:31
  • Bombardier is facing rating updates from Scotiabank, Desjardins, and CIBC, alongside institutional trading disclosures filed with the SEC.Sun 12:48
• Gautam Patel →

  Indian Sanskrit-language writer from Gujarat, India

  Nothing else this week.

Related events

• Expertise is guiding drug development toward regulatory approval, involving the FDA and David Rubenstein.Oct 16
• PAVmed is facing the requirement of regulatory clearance for its company products, while also attracting institutional investment interest.Sep 5
• A company is seeking FDA 510(k) clearance while simultaneously conducting a private placement and qualifying its prospectus in British Columbia.Oct 15
• Medpace filed required documents with the Securities and Exchange Commission on August 15, 2026.Aug 15
• Biohaven filed an update on its NDA with the SEC, while the FDA indicated that advisory committee meetings were unnecessary.Jun 7